Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396050 | 0.83 | KMT2A (0.50) | GPR119MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4402806 | 0.82 | GPR119 (0.54) | GPR119MAPTHRH3ALDH1A1LMNA | |
| SCHEMBL4620879 | 0.81 | GPR119 (0.47) | GPR119CHRM2CHRM1HRH3ALDH1A1 | |
| SCHEMBL3399260 | 0.79 | GPR119 (0.47) | GPR119HRH3SMN1; SMN2LNPEP | |
| SCHEMBL15173617 | 0.78 | ALDH1A1 (0.40) | MAPTHRH3ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15202721 | 0.77 | GPR119 (0.48) | GPR119MAPTHRH3ALDH1A1LMNA | |
| SCHEMBL26131980 | 0.76 | SLC6A2 (0.40) | MAPTALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL4662204 | 0.76 | GPR119 (0.47) | GPR119CHRM2CHRM1HRH3POLB | |
| SCHEMBL23466891 | 0.75 | PDE4B (0.45) | GPR119CHRM2CHRM1MAPTALDH1A1 | |
| SCHEMBL3914633 | 0.75 | MLNR (0.49) | GPR119MAPTHRH3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| EP-1924572-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SmithKline Beecham Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | GPR119 3158/4885CHRM2 3998/4885CHRM1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.